US2010249073A1PendingUtilityA1

Prophylactic and therapeutic treatment of Alzheimer's disease using phytic acid and phytate to reduce amyloid beta plaque and tau protein

60
Assignee: SABIN ROBERTPriority: Mar 27, 2009Filed: Mar 26, 2010Published: Sep 30, 2010
Est. expiryMar 27, 2029(~2.7 yrs left)· nominal 20-yr term from priority
Inventors:Robert Sabin
A61K 31/66A61K 31/6615A61K 9/2004A61K 9/0014A61K 9/19A61P 25/28A61P 25/00A61K 9/0095A61K 9/0021
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition and method for the treatment of Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, amyloidosis and amyotrophic lateral sclerosis, includes an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams per day.

Claims

exact text as granted — not AI-modified
1 . A composition for the treatment of Alzheimer's disease related amyloid plaque development and reduction of amyloid plaque, amyloid plaque protein aggregation and amyloidosis comprising an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams per day. 
     
     
         2 . The composition as in  claim 1  wherein the compound is ingested orally. 
     
     
         3 . The composition as in  claim 1  wherein the compound is administered topically. 
     
     
         4 . The composition as in  claim 1  wherein the compound is administered transdermally. 
     
     
         5 . The composition as in  claim 1  wherein the compound is administered intradermally. 
     
     
         6 . A method for the treatment of Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, amyloid plaque protein aggregation and amyloidosis comprising the steps of administering an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered in an amount from about 0.5 grams to about 18.75 grams per day. 
     
     
         7 . The method as in  claim 6  wherein the compound is ingested orally. 
     
     
         8 . The method as in  claim 6  wherein the compound is administered topically. 
     
     
         9 . The method as in  claim 6  wherein the compound is administered transdermally. 
     
     
         10 . The method as in  claim 6  wherein the compound is administered intradermally. 
     
     
         11 . A composition for the treatment of amyotrophic lateral sclerosis comprising an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams per day. 
     
     
         12 . The composition as in  claim 11  wherein the compound is ingested orally. 
     
     
         13 . The composition as in  claim 11  wherein the compound is administered topically. 
     
     
         14 . The composition as in  claim 11  wherein the compound is administered transdermally. 
     
     
         15 . The composition as in  claim 11  wherein the compound is administered intradermally. 
     
     
         16 . A method for the treatment of amyotrophic lateral sclerosis comprising the steps of administering an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered in an amount from about 0.5 grams to about 18.75 grams per day. 
     
     
         17 . The method as in  claim 16  wherein the compound is ingested orally. 
     
     
         18 . The method as in  claim 16  wherein the compound is administered topically. 
     
     
         19 . The method as in  claim 16  wherein the compound is administered transdermally. 
     
     
         20 . The method as in  claim 16  wherein the compound is administered intradermally.

Join the waitlist — get patent alerts

Track US2010249073A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.